Physician profile
Michael James Baker
NPI 1255487831
$1,514.03
in general payments reported to CMS, 2019-2025
20 companies · $319 in 2025
The $319 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2022: $151 · 2023: $592 · 2024: $298 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $581.92 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $125.96 | 2023-2025 | Entyvio, Eohilia |
| Celgene Corporation | $116.23 | 2022-2023 | Zeposia |
| Pfizer INC. | $90.84 | 2022-2025 | |
| Genzyme Corporation | $87.09 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.82 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $73.04 | 2019-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $51.74 | 2019-2024 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $51.08 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $43.72 | 2023 | Dupixent |
| Ferring Pharmaceuticals INC. | $30.66 | 2019-2023 | Rebyota |
| Madrigal Pharmaceuticals | $26.12 | 2024 | Resmetirom |
| Olympus America INC. | $25.59 | 2025 | Endoclot Phs |
| E.R. Squibb & Sons, L.L.C. | $23.63 | 2024 | Zeposia |
| Merck Sharp & Dohme LLC | $21.35 | 2024 | Dificid |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $18.72 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.73 | 2023 | |
| Aimmune Therapeutics, INC. | $16.62 | 2024 | |
| Qol Medical, LLC | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.